Physician profile
Christopher L Moore
NPI 1942523725
$2,845.91
in general payments reported to CMS, 2019-2025
31 companies · $457 in 2025
The $457 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57.67 · 2020: $528 · 2021: $288 · 2022: $697 · 2023: $412 · 2024: $406 · 2025: $457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,275.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $710.39 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $254.13 | 2020-2025 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $240.97 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $182.60 | 2020-2024 | Xifaxan, Trulance |
| Dexcom, INC. | $160.61 | 2021-2023 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Lilly USA, LLC | $157.45 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Janssen Pharmaceuticals, INC | $134.68 | 2020-2021 | |
| Madrigal Pharmaceuticals | $113.51 | 2024 | Rezdiffra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.76 | 2020-2025 | Jardiance |
| Glaxosmithkline, LLC. | $103.71 | 2020-2023 | Trelegy Ellipta, Bexsero, Pediarix |
| Pfizer INC. | $99.25 | 2020-2021 | |
| Exact Sciences Corporation | $64.91 | 2023-2025 | Cologuard Collection Kit |
| Sunovion Pharmaceuticals INC. | $57.67 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $46.27 | 2024-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $45.28 | 2025 | Caplyta |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $37.15 | 2020-2021 | |
| Shield Therapeutics INC | $35.11 | 2023 | Accrufer |
| Grifols USA, LLC | $34.71 | 2022-2023 | Prolastin-C Liquid |
| Novartis Pharmaceuticals Corporation | $33.80 | 2022 | |
| Lundbeck LLC | $30.34 | 2024 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $28.13 | 2020 | |
| Abbvie INC. | $24.65 | 2021 | |
| Biomarin Pharmaceutical INC. | $21.85 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.42 | 2022 | |
| Verona Pharma, INC. | $16.70 | 2025 | Ohtuvayre |
| Amarin Pharma, INC. | $15.60 | 2020 | |
| Amgen INC. | $15.21 | 2020 | |
| Sumitomo Pharma America, INC. | $14.84 | 2025 | Gemtesa |
| E.R. Squibb & Sons, L.L.C. | $14.46 | 2022 | |
| Daiichi Sankyo INC. | $13.69 | 2022 | |
| Ironwood Pharmaceuticals, INC | $12.06 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.